Lipid management has been part of cardiovascular medicine for decades, but the brain implications have been less emphasized — and the measurements that matter most have only recently been emphasized in clinical practice. The Lancet Commission's 2024 update added LDL cholesterol as a modifiable dementia risk factor with an estimated population-attributable fraction of approximately 7% — one of the larger single factors in the framework. For longevity psychiatry, this elevates lipid optimization from cardiovascular sideline to brain-protection priority.
Why apoB matters more than LDL-C. Atherosclerosis and the small vessel disease that affects the brain are driven by atherogenic lipoprotein particles entering and depositing in vessel walls. LDL cholesterol (LDL-C) measures the cholesterol content of these particles. ApoB (apolipoprotein B) measures the actual number of atherogenic particles directly. The number of particles drives risk; cholesterol content is a downstream variable that can underestimate risk in patients with small dense LDL or with metabolic syndrome features. Two patients with identical LDL-C of 110 mg/dL but apoB values of 90 vs 130 mg/dL have substantially different cardiovascular and cerebrovascular risk profiles. The patient with apoB 130 is being undertreated by LDL-C-targeted care alone.
The cognitive-protection target for apoB is typically more aggressive than the cardiology-event-prevention target. For patients in the acceleration window without established disease, an apoB target under 80 mg/dL (corresponding roughly to LDL-C under 100 with healthy particle composition) is reasonable; for higher-risk patients (family history, established vascular disease, additional risk factors), targets of apoB under 65 or even under 50 are increasingly recommended in longevity-medicine practice. The pharmacological pathway typically begins with statins, adds ezetimibe if needed, and considers PCSK9 inhibitors or bempedoic acid for high-risk patients not at goal.
Midlife lipid status matters more than later-life lipid status for cognitive risk. The Lancet 2024 evidence base focuses on midlife elevated LDL/apoB as the relevant exposure window for later dementia risk. This is consistent with the broader longevity-medicine principle that vascular damage accumulates over decades — the lipid burden in the 40s, 50s, and 60s is what produces the small vessel disease and atherosclerosis that contribute to cognitive decline in the 70s and 80s. The clinical implication is that lipid optimization in midlife is brain medicine in a way that lipid optimization at 75 cannot match.
The patient conversation about statins and apoB often requires reframing. Patients who have read about statin side effects, or who have experienced muscle symptoms attributed to statins, are often hesitant. The longevity-psychiatry framing emphasizes brain protection rather than cardiovascular event prevention — many patients respond differently to "this protects your brain over the next twenty years" than to "this reduces your heart attack risk over the next ten." Muscle symptoms can be addressed by trial of different statins or non-statin agents; documented statin-induced muscle injury is rare though clinically real. The conversation should be honest about the evidence and the realistic side effect profile.
The longevity-psychiatry workup orders apoB at baseline in every patient in the acceleration window, treats to cognitive-protection targets that are typically more aggressive than standard cardiology targets, and revisits the lipid picture annually with attention to whether the trajectory is improving or worsening. Lipoprotein(a) is measured once in a lifetime (covered in L7.4). The integration with the rest of the metabolic workup (Stage 5) and the broader vascular workup (this stage) is the comprehensive approach.